<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02203773</url>
  </required_header>
  <id_info>
    <org_study_id>M14-358</org_study_id>
    <secondary_id>2014-000687-18</secondary_id>
    <nct_id>NCT02203773</nct_id>
  </id_info>
  <brief_title>A Study of ABT-199 in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and
      pharmacokinetics of orally administered ABT-199 combined with decitabine or azacitidine and
      the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction
      (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of ABT-199
      in combination with posaconazole.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 6, 2014</start_date>
  <completion_date type="Anticipated">March 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>Measured up to 2 years after the last subject enrolled has their last study visit.</time_frame>
    <description>Complete Remission Rate will be determined by the number of subjects who achieve a Complete Remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission with incomplete blood count recovery rate</measure>
    <time_frame>Measured up to 2 years after the last subject has their last study visit.</time_frame>
    <description>Complete Remission with incomplete blood count recovery Rate will be determined by the number of subjects who achieve a Complete Remission with incomplete blood count recovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>half-life (t1/2)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The time required for the concentration of the drug to reach half of its original value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>Maximum observed concentration, occurring at Tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Measured up to 2 years after the last subject enrolled has their last study visit.</time_frame>
    <description>Overall response rate will be defined as the proportion of subjects who achieve a complete remission (CR), complete remission incomplete (CRi), or partial remission(PR) per the International Working Group criteria for AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>Clearance is defined as the rate at which drug is cleared from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from 0-24 (AUC0-24)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) over a 24-hour dose interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (peak time, Tmax),</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>The time at which maximum plasma concentration (Cmax) is observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from 0 to infinity (AUCâˆž)</measure>
    <time_frame>For approximately 5 days following a single dose of ABT-199.</time_frame>
    <description>Area under the plasma concentration-versus-time curve from time zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>Overall survival will be defined as the number of days from the date of enrollment to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who move on to stem cell transplant</measure>
    <time_frame>Measure up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>The percent of subjects who move on to stem cell transplant will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>Duration of response will be defined as the number of days from the date of first response per the IWG criteria for AML to the earliest recurrence or progressive disease (PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Measured up to 2 years after the last subject enrolled has their last study visit.</time_frame>
    <description>Event-free survival (EFS) will be defined as the number of days from the date of first dose to the date of earliest evidence of relapse, subsequent treatment other than stem cell transplant while in composite complete response (CR + CRi), or death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelogenous Leukemia</condition>
  <condition>Treatment Naive AML</condition>
  <arm_group>
    <arm_group_label>ABT-199 + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive Acute Myelogenous Leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199 + Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive Acute Myelogenous Leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199+Decitabine+Posaconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Naive Acute Myelogenous Leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.</description>
    <arm_group_label>ABT-199+Decitabine+Posaconazole</arm_group_label>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-199</intervention_name>
    <description>ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.</description>
    <arm_group_label>ABT-199 + Decitabine</arm_group_label>
    <arm_group_label>ABT-199 + Azacitidine</arm_group_label>
    <arm_group_label>ABT-199+Decitabine+Posaconazole</arm_group_label>
    <other_name>venetoclax</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles</description>
    <arm_group_label>ABT-199 + Decitabine</arm_group_label>
    <arm_group_label>ABT-199+Decitabine+Posaconazole</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.</description>
    <arm_group_label>ABT-199 + Azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have confirmation of Acute Myeloid Leukemia (AML) by WHO criteria and be
             ineligible for treatment with a standard cytarabine and anthracycline induction
             regimen due to co-morbidity or other factors.

          -  Subject must have received no prior treatment for AML with the exception of
             hydroxyurea

          -  Subjects must have Eastern Cooperative Oncology Group (ECOG) Performance Status of )
             to 2 for subjects greater than or equal to 75 years of age, or 0 to 3 for subjects
             greater than or equal to 60 to 74 years of age

          -  Subject must have adequate kidney and liver function as described in the protocol

        Exclusion Criteria:

          -  Subject has received treatment with the following hypomethylating agent and/or chemo
             therapeutic agent for for an antecedent hematologic disorder (AHD) (Subjects may have
             been treated with other agents for AHD i.e., Myelodysplastic syndrome [MDS])

          -  Subject has history of Myeloproliferative Neoplasm (MPN).

          -  Subject has favorable risk cytogenetics as categorized by the National Comprehensive
             Cancer Network Guidelines Version 2, 2014 for AML.

          -  Subject has t(8;21), inv(16), t(16;16) or t(15;17) karyotype abnormalities.

          -  Subject has acute promyelocytic leukemia.

          -  Subject has known active central nervous system involvement with AML.

          -  Subject has received a strong and/or moderate CYP3A inducer within 7 days prior to the
             initiation of study treatment.

          -  Subject has a history of other malignancies .prior to study entry, with the exception
             of:

               -  Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of
                  breast;

               -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
                  skin;

               -  Previous malignancy confined and surgically resected (or treated with other
                  modalities) with curative intent.

          -  Subject has a white blood cell count &gt; 25 Ã— 10^9/L. Note: Hydroxyurea is permitted to
             meet this criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comp Cancer Ctr</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX, MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-LÃ©vÃªque</name>
      <address>
        <city>Pessac CEDEX</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Thuringen</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2014</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelogenous Leukemia</keyword>
  <keyword>ABT-199</keyword>
  <keyword>GDC-0199</keyword>
  <keyword>Treatment Naive AML</keyword>
  <keyword>Untreated AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

